Alectinib
Sign in to save this workspacePrimary targets: ALK, RET · FDA status: FDA Approved
Selectivity scorecard
KISS
95.49
Gini
0.651
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Alectinib. Strongest target: SRPK1 at 99.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | SRPK1 | 99.6% | 0.4% |
| 2 | CAMK2D | 99.5% | 0.5% |
| 3 | MSSK1_STK23 | 98.9% | 1.1% |
| 4 | CHK2 | 98.8% | 1.2% |
| 5 | ALK | 98.6% | 1.4% |
| 6 | TYK1_LTK | 98.2% | 1.8% |
| 7 | RET | 97.8% | 2.2% |
| 8 | CAMK2A | 97.7% | 2.3% |
| 9 | PIM3 | 95.1% | 4.9% |
| 10 | PHKG1 | 94.5% | 5.5% |
| 11 | LRRK2 | 94.5% | 5.5% |
| 12 | SRPK2 | 94.4% | 5.6% |
| 13 | FGR | 94.2% | 5.8% |
| 14 | TRKC | 94.2% | 5.8% |
| 15 | CAMKK2 | 93.3% | 6.7% |
| 16 | FLT4_VEGFR3 | 92.8% | 7.2% |
| 17 | LYN | 92.4% | 7.6% |
| 18 | IR | 91.1% | 8.9% |
| 19 | DAPK1 | 89.5% | 10.5% |
| 20 | PHKG2 | 89.3% | 10.7% |
Selectivity landscape
Where Alectinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Alectinib.
Annotations
Sign in to read and post annotations.
Loading…